KRBP.US Kiromic Biopharma Inc

Healthcare Biotechnology USA Stocks
0.0810 USD
Close of Jul 26, 2026
18.11 24.27
Market cap
USD 215K
P/E
-
P/B
11.55x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is KRBP.US undervalued?

Graham number

The Graham number of Kiromic Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kiromic Biopharma Inc fundamental analysis

No fundamental analysis for Kiromic Biopharma Inc yet.

Kiromic Biopharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kiromic Biopharma Inc

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combi…

Full company profile